Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Internship

Pediatrics

Boston Children's Hospital

1994, Boston, MA

Medical School

University of Massachusetts

1993, Worcester, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

1996, Boston, MA

Undergraduate School

University of Pennsylvania

1989, Philadelphia, PA

Fellowship

Pediatric Hematology -Oncology

Children's Hospital of Philadelphia

2000, Philadelphia, PA

Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Publications

  1. Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma. Curr Oncol. 2025 Feb 22; 32(3). View Abstract

  2. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751. View Abstract

  3. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  4. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  5. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 09; 198:110384. View Abstract

  6. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111. View Abstract

  7. STK11 Adnexal Tumor in an Adolescent Female: Diagnostic Pitfalls of a Recently Described Entity. Pediatr Dev Pathol. 2023 Sep-Oct; 26(5):486-493. View Abstract

  8. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  9. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 05; 29(5):1092-1102. View Abstract

  10. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 01 20; 41(3):508-516. View Abstract

  11. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789. View Abstract

  12. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977. View Abstract

  13. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 11; 68(11):e29282. View Abstract

  14. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. View Abstract

  15. Facial Paralysis From Post-transplant Lymphoproliferative Disorder. Otol Neurotol. 2021 06 01; 42(5):e605-e608. View Abstract

  16. Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. Cancer Med. 2021 Apr; 10(7):2310-2318. View Abstract

  17. The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559. View Abstract

  18. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. View Abstract

  19. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. View Abstract

  20. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. View Abstract

  21. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. Clin Cancer Res. 2019 10 15; 25(20):6044-6051. View Abstract

  22. Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). View Abstract

  23. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View Abstract

  24. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract

  25. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View Abstract

  26. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2014 Oct; 61(10):1792-7. View Abstract

  27. Neuroblastoma presenting as facial nerve palsy and bulging tympanic membrane. Clin Pediatr (Phila). 2015 Feb; 54(2):183-5. View Abstract

  28. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. View Abstract

  29. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy. Clin Nucl Med. 2013 Aug; 38(8):604-7. View Abstract

  30. Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma. Clin Cancer Res. 2012 12 15; 18(24):6732-41. View Abstract

  31. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. View Abstract

  32. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. Semin Nucl Med. 2011 Sep; 41(5):354-63. View Abstract

  33. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. View Abstract

  34. Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1057-65. View Abstract

  35. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 01; 29(7):839-44. View Abstract

  36. Genotypes of NK cell KIR receptors, their ligands, and Fc? receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res. 2010 Dec 01; 70(23):9554-61. View Abstract

  37. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. View Abstract

  38. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009 Mar 01; 27(7):1020-5. View Abstract

  39. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006 Jun 15; 66(12):6050-62. View Abstract

  40. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2006.

  41. Expression profiling identifies BAI2, an endogenous inhibitor of angiogenesis, as a traget for somatic inactivation in high-risk neuroblastoma. Advances in Neuroblastoma Research Proceedings. 2006; 73.

  42. 131I-Metaiodobenzylguanidine(131I-MIBG) double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2006; 123.

  43. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005 Oct 18; 228(1-2):171-9. View Abstract

  44. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res. 2005 Apr 01; 11(7):2680-5. View Abstract

  45. Somatic Inactivation of brain-specific angiogenesis inhibitor-2 (BAI2) during the malignant evolution of high-risk neuroblastoma. Pediatric Blood and Cancer. 2005; 44(6).

  46. 131I-MIBG double infusiton with autologous stem cell transplant (ASCT) for neuroblastoma - a New Approaches to Neuroblastoma Therapy (NANT) study. Advances in Neuroblastoma Research Proceedings. 2004; 65.

  47. Genome-wide transcriptome analysis for neuroblastoma gene discovery and refinement of clinical risk group prediction. Advances in Neuroblastoma Research Proceedings. 2004; 103.

  48. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction. Mod Pathol. 2003 Dec; 16(12):1248-56. View Abstract

  49. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15; 63(22):7861-9. View Abstract

  50. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res. 2003 Apr 01; 63(7):1631-5. View Abstract

  51. Functional genomic analysis of neuroblastoma for high resolution mapping of 11q deletions. American Association for Cancer Research Proceedings. 2003; 44:1394.

  52. Neuroblastoma. Holland JC and Frei E, editors. Cancer Medicine. 2003; 2263-76.

  53. Increased incidence of TP53 mutations in post-treatment neuroblastomas. American Association for Cancer Research Proceedings. 2003; 44:809.

  54. Transfusion of the patient with congenitally aquired coagulation defects. Hillyer CD and Silbersteing LE, editors. Principles of Blood Banking and Transfusion Medicine. 2003; 291-306.

  55. Discovery of antiangiogenic targets induced by chemotherapy in a murine model of human neuroblastoma. American Association for Cancer Research Proceedings Late Breaking Abstracts. 2003.

  56. A reversible methionine aminopeptidase inhibitor potently inhibits growth of human neuroblastoma in xenotransplantation models. American Association fo Cancer Research Proceedings. 2003; 44:809.

  57. Transplantation in Hematology and Oncology II. 2003; 283-98.

  58. Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res. 2002 Nov 15; 62(22):6651-8. View Abstract

  59. Chromosome 11q23.3-q24.1 deletions in neuroblastoma (NB). Advances in Neuroblastoma Research Proceedings. 2002; 18.

  60. ID2 is a MYCN target gene, but expression is not correlated with MYCN gene amplification in human neuroblastomas. Advances in Neuroblastoma Research Proceedings. 2002; 50.

  61. Angiogenesis inhibition is an effective adjuvant therapeutic strategy in neuroblastoma (NB) preclinical models. Advances in Neuroblastoma Research Proceeddings. 2002; 87.

  62. A combined functional and expression profiling strategy for isolating neuroblastoma suppresso genes on chromosome 11. American Association for Cancer Research Proceedings. 2002; 43:343.

  63. Prospective validation of real-time quantitative PCR for detection of MYCN amplifcation inprimary neuroblastoma specimens. Advances in Neuroblastoma Research Proceedings. 2002; 67.

  64. A functional and expression profiling stratefy for isolating neuroblastoma (NB) supressor genes on chromosome 11. Advances in Neuroblastoma Research Proceedings. 2002; 18.

  65. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res. 2001 Apr; 7(4):977-84. View Abstract

  66. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32. View Abstract

  67. The growth rate of human neuroblastoma xenografts is decreased through inhibition of multiple angiogenic signaling pathways with SU668. Journal of Pediatric Hematology/Oncology . 2001; 23:A1.

  68. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth especially in the setting of subclinical disease. Clinical Cancer Research. 2001; 7(4):977-84.

  69. Inhibition of the VEGF, PDGF and bFGF signaling pathways with SU6668 decreases the growth rate of human neuroblastoma xenografts. American Association for Cancer Research Proceedings. 2001; 42:803.

  70. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol. 2000 Dec; 35(6):526-30. View Abstract

  71. Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol. 2000 Dec; 35(6):673-6. View Abstract

  72. Long term survivors of childhood leukemia. Curr Opin Hematol. 2000 Jul; 7(4):217-22. View Abstract

  73. Effects of TRK receptor expression on angiogenesis in neuroblastoma cells. American Association for Cancer Research Proceedings. 2000; 41:791.

  74. Detection of unbalanced 17q gain in human neuroblastomas by real-time quantitative PCR. American Association for Cancer Research Proceedings. 2000; 41:791.

  75. Use of real-time quantitative PCR to detect unbalanced 17q gain in neuroblastoma cell lines and primary tumors. Medical and Pediatric Oncology. 2000; 35:748.

  76. Microcytic Anemia. Iron Deficiency Anemia. The 5 Minute Pediatric Consult. 2000.

  77. Inhibitors of angiogenesis in minimal residual disease: safety post-BMT and efficacy in a preclinical model. Angiogenesis in Oncology and Hematology. 2000.

  78. Preclinical evaluation of antiangiogenic therapy with TNP-470 for human neuroblastoma. Molecular Targets and Cancer Therapeutics. 1999; 5:3812s.

  79. TNP-470 inhibits the growth rate and tumorigenicity of human neuroblastoma xenografts. Journal of Pediatric Hematology/Oncology. 1999; 21:326.

  80. A 2.5-month-old girl with hyperbilirubinemia, hypoglycemia, and blindness. Curr Opin Pediatr. 1996 Aug; 8(4):411-6. View Abstract
BESbswy